Congress passed a bill banning fentanyl analogues, but also allowing more research into marijuana and other Schedule I drugs. The House approved the HALT Fentanyl Act, which streamlines research into Schedule I drugs like marijuana, but critics worry it will increase mandatory minimum sentences. The bill also aims to expedite registrations for studies into Schedule I drugs.

Fentanyl Bill on Trump’s Desk Includes Easier Cannabis Research Provisions

Jun 13, 2025

Source:

Kyle Jaeger

Marijuana Moment

A new bill headed to the President’s desk is causing quite a stir, and it’s a bit of a mixed bag for the cannabis community. Known as the HALT Fentanyl Act, the legislation primarily aims to crack down on fentanyl analogues. However, tucked inside are some surprisingly progressive wins for marijuana research. The bill cuts through the typical federal red tape, making it much easier for scientists to study Schedule I substances. By streamlining DEA registration and allowing researchers at the same institution to share data more freely, we might finally get the high-quality, domestic studies we’ve been waiting for.

While the bill's focus on harsher sentencing feels like a step backward toward old-school prohibition tactics, the research boost is a massive silver lining. For everyday tokers, this matters because more research leads to better product safety standards and reinforces the medical legitimacy of the plant. It’s a classic case of political compromise, but more science in the hands of experts is always a win for a community built on transparency and accessibility.